Informations générales (source: ClinicalTrials.gov)

NCT02941289 Statut inconnu
Visuospatial Attention and Eye Movement Behaviour in Patients With Alzheimer's Disease When Searching in Realistic Scenes and a Natural Setting: Exploring Perceptual and Cognitive Mechanisms and Their Relationships With IADLs (ARVA-MA)
Interventional
  • Maladie d'Alzheimer
N/A
Centre Hospitalier Universitaire de Nice (Voir sur ClinicalTrials)
novembre 2016
mai 2019
29 juin 2024
The aim is to understand which components of attentional deployment and selection are impaired in AD during searching in realistic scenes on a computer screen (Experiment 1) and in a natural setting (Experiment 2).The investigators will also examine how deficits in visual exploration may be related to impairments in semantic, long-term memory (LTM) and working memory (WM) representations by manipulating the semantic consistency between the target and its visual surroundings, and the type of target cue (abstract vs. precise), respectively. Perceptual saliency of target and distractor objects will be also manipulated in Expt.1, In Expt.2, in order to determine how deficits in visual exploration may be involved in the IADL deficits shown by AD patients, participants at each trial will be required to search in a natural settings different types of targets and then to perform an IADL using five objects, among which one of the searched targets. Measures analysed: for the search tasks (Expt. 1 and 2): eye movements in different search phases, accuracy and response times; for IADLs tasks (Expt. 2): eye movements during action planning and execution, motor efficiency (number and types of action performed), time to terminate the activity. Compared to controls, the investigators expect that AD patients will have reduced ability using scene semantic LTM in order to locate the objects, greater attentional capture from highly salient features and greater search performance impairment when higher WM resources are required (abstract target cues). The investigators also expect that their performance at IADLs will be less efficient and, in particular, less organized than control, with reduced advantage of eye guidance.
 Voir le détail

Etablissements

Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données
CHU de Nice - Nice - France Vanina OLIVERI, project manager En recrutement Contact (sur clinicalTrials)

Critères

Tous
Inclusion Criteria: Control participants

- Male and female

- Age between 65 and 75 years old

- MMSE score equal or > 27

- Normal visual acuity (with or without correction to normality)

- Subjects with a score of 0 on " tremors " and " rigidity " items of UPDRS III scale

- Subjects without major depression criteria according to DSM IV-R

- No apathy according to diagnostic criteria of apathy

- Signed informed consent

Inclusion Criteria: Alzheimer's disease patients

- Male and female

- Age between 65 and 75 years old

- Probable diagnosis of Alzheimer's disease with a mild impairment (MMSE 20-26)
according to DSM IV diagnosis criteria

- Normal visual acuity (with or without correction to normality)

- Subjects with a zero score on " tremors " and " rigidity " items of UPDRS III scale

- Signed informed consent



- Controls with neurological and/or psychiatric pathologies

- AD patients with neurological and/or psychiatric pathologies unrelated to AD

- AD patients with vascular dementia suspicion in addition to the probable diagnosis
of AD

- AD patients with MMSE score < 20

- Individuals with abnormal visual acuity (i.e., glaucoma, cataract sufficiently
severe that limited vision...)

- Individuals with motor disorders, Parkinsonism...

- Receiving drug treatments that could alter cognitive functions